Side-by-side · Research reference

TestagenvsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/41 cited

BHuman-MechanisticAUTO-DRAFTED12/40 cited

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

Testagen

Thymalin

Primary target

Testicular tissue; proposed nuclear DNA interaction

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

Unknown — no HPG axis data

—

Origin

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

Testagen

Thymalin

Typical protocol (anecdotal)

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

—

Frequency

Once daily or alternate days

Once daily during cycle

Cycle length

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

—

Evidence basis

Animal mechanistic / in vitro onlyFedoreyeva 2011

Russian clinical + in vitroKhavinson 2002

Route

Subcutaneous

—

Reconstitution

Sterile water or bacteriostatic saline

Saline or bacteriostatic water

Half-life

Unknown — likely minutes (short peptide)

Hours (estimated)

Standard dose

—

5–10 mg / day IM × 5–10 daysKhavinson 2002

Lower / starter dose

—

2.5 mg / day

Duration

—

5–10 day cycles, 1–2× per year

Timing

—

Morning preferred

04Side Effects & Safety

Parameter

Testagen

Thymalin

Injection site reactions

Erythema, mild irritation (potential)

—

Systemic effects

Unknown — no human safety data

—

Hormonal impact

No published data on testosterone, LH, FSH effects

—

Long-term safety

Unknown — no long-term studies

Limited Western data

Injection site reaction

—

Mild erythema at IM site

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Pregnancy / OB

—

Avoid

Absolute Contraindications

Testagen

·Active testicular malignancy

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

Testagen

Thymalin

1. Reconstitution

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

Intramuscular — deltoid or gluteal. Rotate sites.

3. Timing

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

Morning preferred during cycle.

4. Storage

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Cycle protocol

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

23–25G, 25–38 mm IM needle.

06Stack Synergy

Testagen

— no documented stacks

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001